Authors
Latest:
R Tyler Hillman, MD, PhD, on Important Contributors Needed to Treat Ovarian Granulosa Cell TumorsAn expert emphasizes how a big team is needed to properly employ the different therapeutic modalities needed to treat patients with ovarian granulosa cell tumors.
Latest:
Sjögren Syndrome Induced by Immune Checkpoint Inhibitors in a Patient with Advanced Renal Cell CarcinomaThis clinical quandary details a Mexican man, aged 77 years, who presented to the oncology clinic with a sternal mass. Based on the results, the patient fulfilled the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for Sjögren syndrome, thus the diagnosis triggered by immune checkpoint inhibitors was definitively established.
Latest:
Immunotherapy Continues to Influence Perioperative Bladder Cancer ManagementAt the recent 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Jean Hoffman-Censits, MD, reviews advances in the use of systemic therapy to aid surgical management of bladder cancer.
Latest:
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell CarcinomaIn this installment of Clinical Quandaries, Justine Panian, BS, and colleagues present a case of a 60-year-old Mexican woman with fevers, abdominal pain, and hypertension.
Latest:
Patient Advocate Speaks to Value of Communicating Developments in Breast CancerProviders should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Latest:
Gathering the Latest Multidisciplinary Care Insights Across World GU 2025Panelists and presenters attending World GU 2025 shared their perspectives on optimizing the management of prostate, kidney, and bladder cancers.
Latest:
CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple MyelomaPanelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.
Latest:
Valentina Boni, MD, PhD, on Breast Cancer Advances from 2022 ASCOValentina Boni, MD, PhD, spoke about numerous trials in the breast cancer space presented at 2022 ASCO.
Latest:
Jeffrey Graham, MD, Talks Immunotherapy Use in Frontline Non-Clear Cell RCCCancerNetwork® sat down with Jeffrey Graham, MD, FRCPC, to discuss the effectiveness of immune checkpoint inhibitors as frontline therapy for non–clear cell renal cell carcinoma
Latest:
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast CancerPatients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
Latest:
Future Perspectives on MRD Testing in Colorectal CancerThe expert panel concludes its discussion with a focus on the future of MRD testing in colorectal cancer, highlighting the treatment landscape’s current strengths and challenges.
Latest:
Provider Perspectives on Managing EGFRm NSCLCPanelists discuss how dermatologic adverse events with EGFR inhibitors are more severe than previously seen with third-generation tyrosine kinase inhibitors, requiring reactive management strategies including topical steroids, antibiotics, and dermatologic consultations that are often difficult to obtain.
Latest:
Updates in Surgical Management of the AxillaAxillary management of patients with breast cancer such as sentinel lymph node biopsy have evolved substantially over the past 30 years.
